Diabetes Drugs Industry Research Report 2024

Diabetes Drugs Industry Research Report 2024


Summary

Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.
According to APO Research, the global Diabetes Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Diabetes Drugs include Sanofi, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Dongbao Pharmaceutical, Eli Lilly, Ganlee and Ginwa, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetes Drugs.
The report will help the Diabetes Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Diabetes Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Sanofi
AstraZeneca
Bayer
Biocon
Boehringer Ingelheim
Dongbao Pharmaceutical
Eli Lilly
Ganlee
Ginwa
Guangzhou Baiyun Mountain
Hisun Pharmacy
Hua Dong
Huadong Medicine
Jumpcan Pharmacy
KELUN
Merck & Co.
MSD
North China Pharmaceutical Group Corporation
Novartis
Novo Nordisk
Sanofi
SHIJIAZHUANG YILING PHARMACEUTICAL
Takeda
Taloph
Tianan Pharmaceutical
Tonghua DongBao
Wanbang Biopharmaceuticals
Diabetes Drugs segment by Type

Insulin
DPP-4
GLP-1
SGLT-2
Diabetes Drugs segment by Application

Type 1 Diabetes
Type 2 Diabetes
Diabetes Drugs Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetes Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Diabetes Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Diabetes Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Diabetes Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Diabetes Drugs Market Size (2019-2030) & (US$ Million)
2.2.2 Global Diabetes Drugs Sales (2019-2030)
2.2.3 Global Diabetes Drugs Market Average Price (2019-2030)
2.3 Diabetes Drugs by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 Insulin
2.3.3 DPP-4
2.3.4 GLP-1
2.3.5 SGLT-2
2.4 Diabetes Drugs by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Type 1 Diabetes
2.4.3 Type 2 Diabetes
3 Market Competitive Landscape by Manufacturers
3.1 Global Diabetes Drugs Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Diabetes Drugs Sales (M Units) of Manufacturers (2019-2024)
3.3 Global Diabetes Drugs Revenue of Manufacturers (2019-2024)
3.4 Global Diabetes Drugs Average Price by Manufacturers (2019-2024)
3.5 Global Diabetes Drugs Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Diabetes Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Diabetes Drugs, Product Type & Application
3.8 Global Manufacturers of Diabetes Drugs, Date of Enter into This Industry
3.9 Global Diabetes Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi
4.1.1 Sanofi Company Information
4.1.2 Sanofi Business Overview
4.1.3 Sanofi Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Sanofi Diabetes Drugs Product Portfolio
4.1.5 Sanofi Recent Developments
4.2 AstraZeneca
4.2.1 AstraZeneca Company Information
4.2.2 AstraZeneca Business Overview
4.2.3 AstraZeneca Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.2.4 AstraZeneca Diabetes Drugs Product Portfolio
4.2.5 AstraZeneca Recent Developments
4.3 Bayer
4.3.1 Bayer Company Information
4.3.2 Bayer Business Overview
4.3.3 Bayer Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Bayer Diabetes Drugs Product Portfolio
4.3.5 Bayer Recent Developments
4.4 Biocon
4.4.1 Biocon Company Information
4.4.2 Biocon Business Overview
4.4.3 Biocon Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Biocon Diabetes Drugs Product Portfolio
4.4.5 Biocon Recent Developments
4.5 Boehringer Ingelheim
4.5.1 Boehringer Ingelheim Company Information
4.5.2 Boehringer Ingelheim Business Overview
4.5.3 Boehringer Ingelheim Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Boehringer Ingelheim Diabetes Drugs Product Portfolio
4.5.5 Boehringer Ingelheim Recent Developments
4.6 Dongbao Pharmaceutical
4.6.1 Dongbao Pharmaceutical Company Information
4.6.2 Dongbao Pharmaceutical Business Overview
4.6.3 Dongbao Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Dongbao Pharmaceutical Diabetes Drugs Product Portfolio
4.6.5 Dongbao Pharmaceutical Recent Developments
4.7 Eli Lilly
4.7.1 Eli Lilly Company Information
4.7.2 Eli Lilly Business Overview
4.7.3 Eli Lilly Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Eli Lilly Diabetes Drugs Product Portfolio
4.7.5 Eli Lilly Recent Developments
4.8 Ganlee
4.8.1 Ganlee Company Information
4.8.2 Ganlee Business Overview
4.8.3 Ganlee Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Ganlee Diabetes Drugs Product Portfolio
4.8.5 Ganlee Recent Developments
4.9 Ginwa
4.9.1 Ginwa Company Information
4.9.2 Ginwa Business Overview
4.9.3 Ginwa Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Ginwa Diabetes Drugs Product Portfolio
4.9.5 Ginwa Recent Developments
4.10 Guangzhou Baiyun Mountain
4.10.1 Guangzhou Baiyun Mountain Company Information
4.10.2 Guangzhou Baiyun Mountain Business Overview
4.10.3 Guangzhou Baiyun Mountain Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Guangzhou Baiyun Mountain Diabetes Drugs Product Portfolio
4.10.5 Guangzhou Baiyun Mountain Recent Developments
4.11 Hisun Pharmacy
4.11.1 Hisun Pharmacy Company Information
4.11.2 Hisun Pharmacy Business Overview
4.11.3 Hisun Pharmacy Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.11.4 Hisun Pharmacy Diabetes Drugs Product Portfolio
4.11.5 Hisun Pharmacy Recent Developments
4.12 Hua Dong
4.12.1 Hua Dong Company Information
4.12.2 Hua Dong Business Overview
4.12.3 Hua Dong Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.12.4 Hua Dong Diabetes Drugs Product Portfolio
4.12.5 Hua Dong Recent Developments
4.13 Huadong Medicine
4.13.1 Huadong Medicine Company Information
4.13.2 Huadong Medicine Business Overview
4.13.3 Huadong Medicine Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.13.4 Huadong Medicine Diabetes Drugs Product Portfolio
4.13.5 Huadong Medicine Recent Developments
4.14 Jumpcan Pharmacy
4.14.1 Jumpcan Pharmacy Company Information
4.14.2 Jumpcan Pharmacy Business Overview
4.14.3 Jumpcan Pharmacy Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.14.4 Jumpcan Pharmacy Diabetes Drugs Product Portfolio
4.14.5 Jumpcan Pharmacy Recent Developments
4.15 KELUN
4.15.1 KELUN Company Information
4.15.2 KELUN Business Overview
4.15.3 KELUN Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.15.4 KELUN Diabetes Drugs Product Portfolio
4.15.5 KELUN Recent Developments
4.16 Merck & Co.
4.16.1 Merck & Co. Company Information
4.16.2 Merck & Co. Business Overview
4.16.3 Merck & Co. Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.16.4 Merck & Co. Diabetes Drugs Product Portfolio
4.16.5 Merck & Co. Recent Developments
4.17 MSD
4.17.1 MSD Company Information
4.17.2 MSD Business Overview
4.17.3 MSD Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.17.4 MSD Diabetes Drugs Product Portfolio
4.17.5 MSD Recent Developments
4.18 North China Pharmaceutical Group Corporation
4.18.1 North China Pharmaceutical Group Corporation Company Information
4.18.2 North China Pharmaceutical Group Corporation Business Overview
4.18.3 North China Pharmaceutical Group Corporation Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.18.4 North China Pharmaceutical Group Corporation Diabetes Drugs Product Portfolio
4.18.5 North China Pharmaceutical Group Corporation Recent Developments
4.19 Novartis
4.19.1 Novartis Company Information
4.19.2 Novartis Business Overview
4.19.3 Novartis Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.19.4 Novartis Diabetes Drugs Product Portfolio
4.19.5 Novartis Recent Developments
4.20 Novo Nordisk
4.20.1 Novo Nordisk Company Information
4.20.2 Novo Nordisk Business Overview
4.20.3 Novo Nordisk Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.20.4 Novo Nordisk Diabetes Drugs Product Portfolio
4.20.5 Novo Nordisk Recent Developments
4.21 Sanofi
4.21.1 Sanofi Company Information
4.21.2 Sanofi Business Overview
4.21.3 Sanofi Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.21.4 Sanofi Diabetes Drugs Product Portfolio
4.21.5 Sanofi Recent Developments
4.22 SHIJIAZHUANG YILING PHARMACEUTICAL
4.22.1 SHIJIAZHUANG YILING PHARMACEUTICAL Company Information
4.22.2 SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
4.22.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.22.4 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Product Portfolio
4.22.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
4.23 Takeda
4.23.1 Takeda Company Information
4.23.2 Takeda Business Overview
4.23.3 Takeda Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.23.4 Takeda Diabetes Drugs Product Portfolio
4.23.5 Takeda Recent Developments
4.24 Taloph
4.24.1 Taloph Company Information
4.24.2 Taloph Business Overview
4.24.3 Taloph Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.24.4 Taloph Diabetes Drugs Product Portfolio
4.24.5 Taloph Recent Developments
4.25 Tianan Pharmaceutical
4.25.1 Tianan Pharmaceutical Company Information
4.25.2 Tianan Pharmaceutical Business Overview
4.25.3 Tianan Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.25.4 Tianan Pharmaceutical Diabetes Drugs Product Portfolio
4.25.5 Tianan Pharmaceutical Recent Developments
4.26 Tonghua DongBao
4.26.1 Tonghua DongBao Company Information
4.26.2 Tonghua DongBao Business Overview
4.26.3 Tonghua DongBao Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.26.4 Tonghua DongBao Diabetes Drugs Product Portfolio
4.26.5 Tonghua DongBao Recent Developments
4.27 Wanbang Biopharmaceuticals
4.27.1 Wanbang Biopharmaceuticals Company Information
4.27.2 Wanbang Biopharmaceuticals Business Overview
4.27.3 Wanbang Biopharmaceuticals Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)
4.27.4 Wanbang Biopharmaceuticals Diabetes Drugs Product Portfolio
4.27.5 Wanbang Biopharmaceuticals Recent Developments
5 Global Diabetes Drugs Market Scenario by Region
5.1 Global Diabetes Drugs Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Diabetes Drugs Sales by Region: 2019-2030
5.2.1 Global Diabetes Drugs Sales by Region: 2019-2024
5.2.2 Global Diabetes Drugs Sales by Region: 2025-2030
5.3 Global Diabetes Drugs Revenue by Region: 2019-2030
5.3.1 Global Diabetes Drugs Revenue by Region: 2019-2024
5.3.2 Global Diabetes Drugs Revenue by Region: 2025-2030
5.4 North America Diabetes Drugs Market Facts & Figures by Country
5.4.1 North America Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Diabetes Drugs Sales by Country (2019-2030)
5.4.3 North America Diabetes Drugs Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Diabetes Drugs Market Facts & Figures by Country
5.5.1 Europe Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Diabetes Drugs Sales by Country (2019-2030)
5.5.3 Europe Diabetes Drugs Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Diabetes Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Diabetes Drugs Sales by Country (2019-2030)
5.6.3 Asia Pacific Diabetes Drugs Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Diabetes Drugs Market Facts & Figures by Country
5.7.1 Latin America Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Diabetes Drugs Sales by Country (2019-2030)
5.7.3 Latin America Diabetes Drugs Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Diabetes Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Diabetes Drugs Sales by Country (2019-2030)
5.8.3 Middle East and Africa Diabetes Drugs Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Diabetes Drugs Sales by Type (2019-2030)
6.1.1 Global Diabetes Drugs Sales by Type (2019-2030) & (M Units)
6.1.2 Global Diabetes Drugs Sales Market Share by Type (2019-2030)
6.2 Global Diabetes Drugs Revenue by Type (2019-2030)
6.2.1 Global Diabetes Drugs Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Diabetes Drugs Revenue Market Share by Type (2019-2030)
6.3 Global Diabetes Drugs Price by Type (2019-2030)
7 Segment by Application
7.1 Global Diabetes Drugs Sales by Application (2019-2030)
7.1.1 Global Diabetes Drugs Sales by Application (2019-2030) & (M Units)
7.1.2 Global Diabetes Drugs Sales Market Share by Application (2019-2030)
7.2 Global Diabetes Drugs Revenue by Application (2019-2030)
7.2.1 Global Diabetes Drugs Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Diabetes Drugs Revenue Market Share by Application (2019-2030)
7.3 Global Diabetes Drugs Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Diabetes Drugs Value Chain Analysis
8.1.1 Diabetes Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Diabetes Drugs Production Mode & Process
8.2 Diabetes Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Diabetes Drugs Distributors
8.2.3 Diabetes Drugs Customers
9 Global Diabetes Drugs Analyzing Market Dynamics
9.1 Diabetes Drugs Industry Trends
9.2 Diabetes Drugs Industry Drivers
9.3 Diabetes Drugs Industry Opportunities and Challenges
9.4 Diabetes Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings